(300 WORDS MAX.) Alzheimer's disease is characterized a number of pathological features that are all implicated in the etiology. These include neuroinflammation, neurovascular alterations, and altered immune functioning, as well as the hallmarks of beta-amyloid deposits and neurofibrillary tangles. In order to effectively treat AD, we speculate that it will be necessary to simultaneously target these various features. We are currently conducting a Phase 1 clinical trial to test a novel cell therapy, called Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs), for which evidence suggest can simultaneously all of the aforementioned pathological features. The goal of the study proposed here is to develop biomarkers that demonstrate target engagement of the novel potential AD therapeutic, Longeveron Mesenchymal Stem Cells (LMSCs), as well as to reliably monitor treatment efficacy and duration of action. Biomarkers will be clinically assessed in three different domains related to AD for which LMSCs are hypothesized to target: inflammation; vascular functioning, and immune functioning. With this grant support, we anticipate being able to accelerate our AD treatment program, and expedite bringing a much needed to market for this indication.